Expert View: The Falsified Medicines Directive

28 March 2016

In our weekly expert view piece, Mark De Simone, chief executive of Aegate, a company which operates a highly secure real-time system to verify the authenticity of medicines, examines the recently published Falsified Medicines Directive (FMD).

Europe stands on the brink of a new world of improved patient safety, increased pharmaceutical supply chain transparency and potential healthcare cost savings. All as the result of the new EU legislation – the Falsified Medicines Directive (FMD).

Ahead is a huge change management project for all members of the pharmaceutical supply chain - from the production of medicines through to the final delivery to patients.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK